ACM
AXSM icon

Atika Capital Management’s Axsome Therapeutics AXSM Stock Holding History

Atika Capital Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,250
Closed -$5.58M – 70
2022
Q3 		$5.58M Buy
1,250
+250
+25% +$12.5K 0.47% 68
2022
Q2 		$3.83M Buy
+1,000
New +$31.6K 0.43% 57

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Atika Capital Management's AXSM Position: Q1 2026 in Review

Atika Capital Management sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 55,500 shares — an estimated $10.1M sold.

Atika Capital Management first reported a position in AXSM in Q2 2022 and held it in 15 quarters. The position peaked at $17.5M in Q4 2022. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • Atika Capital Management reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Atika Capital Management sold 55,500 Axsome Therapeutics shares in Q1 2026, an estimated $10.1M.
  • Atika Capital Management first reported a position in Axsome Therapeutics in Q2 2022 and held it in 15 quarters.
  • Atika Capital Management's Axsome Therapeutics position peaked at $17.5M in Q4 2022.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Atika Capital Management's 13F filing for Q1 2026, filed 14 May 2026.